Korting 2001.

Methods	RCT Study aim clearly defined: yes Blinded assessor of primary outcome: yes Double blind study: yes Participants comparable at baseline for age: yes Sex: yes Duration of complaint: yes stated Inclusion and exclusion criteria specified: yes Interventions well described: yes Assessment of compliance: not stated Intention to treat analysis: yes A Priori sample size calculation: not stated. Fungi identified: no Distribution of species between groups: no Adverse events reported: reported none occurred Number of drop outs stated: 30
Participants	Total evaluable sample size: 70 Exclusion criteria;concomitant toenail/finger nail onychomycosis, use of cytotoxic immunosuppressants.
Interventions	a. Terbinafine cream 1% 7 days once daily. b. Placebo (vehicle cream) seven days once daily.
Outcomes	Primary outcome: cure Secondary outcomes: Total clinical signs and symptoms and clinical response.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	D ‐ Not used